Clinical Trial Update: Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of Galiximab for relapsed or refractory Hodgkin lymphoma has completed; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Galiximab (galiximab)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2015-02-04